Tasly Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jing Su

Algemeen directeur

CN¥2.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Jing Su (61 yo)

no data

Tenure

CN¥2,659,900

Compensatie

Mr. Jing Su is General Manager and Director of Tasly Pharmaceutical Group Co., Ltd.

Tasly Pharmaceutical Group Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Upcoming dividend of CN¥0.26 per share

Investor sentiment improves as stock rises 18%

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 2Q 2023)

Now 23% overvalued

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Now 20% overvalued

Dividend of CN¥0.33 announced

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.72 (vs CN¥0.18 loss in FY 2022)

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Full year 2022 earnings released: CN¥0.17 loss per share (vs CN¥1.57 profit in FY 2021)

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥1.57 (vs CN¥0.75 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day low: CN¥13.57

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥14.49

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61

Revenue misses expectations

Earnings released

Chongqing Pharmaceutical (Group) Co., Ltd. completed the acquisition of Tianjin Tasly Medicine Distribution Group CO.,LTD. from a group of shareholders.

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensatie